Denmark approves Sativex as treatment of spasticity due to MS
Developed by GW Pharmaceuticals, Sativex (Delta-9-Tetrahydro-cannabinol (THC) and Cannabidiol (CBD)) is in phase III clinical development for the treatment of cancer pain, as the next indication following MS
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.